Search Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseBone MetastasesHypercalcemia of MalignancyOsteolysisSubgroupICD10C79.5E83.59M89.5-MeSHHypercalcemiaOsteolysisSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDenosumabZoledronic AcidSupportive substanceBalanced Crystalloid SolutionDenosumabZoledronic AcidSupportive substanceBalanced Crystalloid SolutionDenosumabZoledronic AcidSupportive substanceBalanced Crystalloid SolutionDenosumabZoledronic AcidNo. Substances12Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentionsupportiveRisksBone PainDiarrheaDyspneaHeadacheHypophosphatemiaOsteonecrosis of the JawRenal Failure only studiesPublicationAuthorLipton ARosen LDiseaseBrustkrebs bedingte Knochenmetastasenmind. 1 Knochenmetastase beim Mamma-Ca mit ECOG 0-2 oder 1 osteolytsche Läsion beim MM Stadium IIIOriginDevelopmental Therapeutics, Cancer Institute Medical Group, Santa Monica, CaliforniaPenn State Milton S. Hershey Medical Center Oncology, Hershey, PAProtocols in Revision 2 protocols foundProtocols under revision.Denosumab 120, Bone Metastases (PID541 V1.1)Zoledronate 4, Bone Metastases (PID936 V1.0)
